65,437 trials
Pandemic H5N1 Influenza
Primary: The Percentages Of Subjects Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 12; 10; 81; 63 Percentages of subjects
Aging
Primary: Cutaneous Blood Flow Response to Local Heating of the Skin. — 68; 70 percent change in mean skin blood flow
Other Reconstructive Surgery
Primary: Pain Score Measured by Visual Analog Scale — 3.48; 1.67 units on a scale — p=<0.01
Aging · Physical Fitness
Primary: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 9 Months — 1.3; 1.5; 0.9 Percentage change in lumbar spine BMD
Carcinoma, Squamous Cell
Primary: Metabolic Response of Target Lesions Assessed as the Change in Standardized Uptake Values (SUV) Max on FDG-PET/CT — -21 percentage of change
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving 28 Joint Disease Activity Score (DAS28) Less Than or Equal to (≤) 3.2 at Week 88 — 82.6; 79.1; 42.6 percentage of participants…
Malignant Melanoma
Primary: Percentage of Participants With Adverse Events (AEs) — 96; 83; 92; 17 percentage of participants
Glioblastoma Multiforme
Primary: Percentage of Participants Alive 6 Months After Start of Treatment — 62.07; 73.33 percentage of participants — p=0.4291
Hereditary Angioedema
Primary: Time to Beginning of Relief of Symptoms — 90; 152 minutes
Stroke
Primary: Feasibility of Recruitment Process — 120; 49; 20; 12 participants
Prophylaxis: Influenza
Primary: Immunologic Equivalence of 3 Consecutive Influenza Vaccine (TIVc) Production Lots. — 667; 738; 655; 466 Titers
Colorectal Cancer
Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707
Pancreatic Cancer
Primary: Part 1: Maximum Tolerated Dose (MTD) of Capecitabine — 900 mg/m^2 BID
Carcinoma, Hepatocellular
Primary: Maximum Tolerated Dose in Phase I — 200; 200 mg bid
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants